Perioperative Reduction of Inapparent Myocardial Injury (PRIME)
Recent data suggests that subclinical myocardial injury occurs in patients undergoing major abdominal surgery, and the degree of damage is proportionally linked to morbidity and mortality in the short and medium terms. Therefore, new methods of limiting myocardial damage are urgently needed.
Ischemic preconditioning is a phenomenon whereby a brief non-lethal ischemia-reperfusion stimulus gives a protective effect to further ischemic insults. In remote ischemic preconditioning (RIPC), this initial stimulus is carried out away from the region of interest, normally a limb. In meta-analysed syntheses the effect size of RIPC in reducing cardiac damage during bypass grafting, as characterised by troponin release, seems to be about 35%.
The PRIME Study will assess the value of RIPC in reducing subclinical myocardial injury in patients undergoing major abdominal surgery. Post-operative troponin release will be used as a surrogate marker of myocardial damage. There is no good data on which to build a reliable sample size calculation, therefore we estimated samples sizes using supplementary data from the recent VISION study. The investigators intend to build a clinically powered study from the results of this study.
Study design will be by single-centre single-blind randomised control trial. Allocation will be 1:1. All treatments will be carried after induction of anaesthesia, prior to surgery. In the RIPC-treatment group, a blood pressure cuff inflated on an upper limb to 200mmHg for 5 minutes, and then deflated for 5 minutes, repeated in three cycles. In the control group, the blood pressure cuff will not be inflated, but the patient will remain under anaesthesia for the same amount of time.
Primary endpoint will be peak post-operative 5th generation hs-TnT (highly sensitive Troponin-T, ng/ml). Secondary endpoint will be hs-TnT area-under-the-curve, major adverse cardiovascular events, serious surgical complications, non-cardiovascular death, quality of life, and length of stay.
Perioperative Myocardial Injury
Procedure: Remote ischaemic preconditioning
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||Effect of Remote Ischemic Preconditioning on Subclinical Myocardial Injury in Major Abdominal Surgery: a Randomised Controlled Trial|
- Peak post-operative troponin (ng/L) [ Time Frame: At 6-12, 24, 48, 72h ]
- Any major adverse cardiovascular events [ Time Frame: 30 days ]"MACCE" - defined as any new arrhythmia, myocardial infarction, congestive heart failure, angina, stroke or non-fatal cardiac arrest, or cerebrovascular or cardiovascular death
- Any serious surgical complications [ Time Frame: 30 days ]'SSG' - defined as any post-operative complication requiring radiological, surgical, or endoscopic intervention, or intensive care, or leading to non-vascular death (i.e. Calvien-Dindo III-V).
- Area-under-the-curve post-operative troponin (ng/L) [ Time Frame: 72 hours ]
- Positive post-operative troponin (binary endpoint, >20ng/L) [ Time Frame: 72 hours ]
|Study Start Date:||June 2013|
|Estimated Study Completion Date:||March 2017|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Active Comparator: Intervention
Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
|Procedure: Remote ischaemic preconditioning|
Sham Comparator: Control
Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01850927
|Royal Berkshire Hospital|
|Reading, Berks, United Kingdom, RM7 0AG|
|Study Director:||Andrew Walden, MBBS PhD MRCP||Royal Berkshire Hospitals|
|Principal Investigator:||Stefan S Antonowicz, MBChB MRCS||Royal berkshire Hospitals|